Last reviewed · How we verify
UI030
At a glance
| Generic name | UI030 |
|---|---|
| Sponsor | Korea United Pharm. Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Arformoterol/Budesonide for COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UI030 CI brief — competitive landscape report
- UI030 updates RSS · CI watch RSS
- Korea United Pharm. Inc. portfolio CI